Nura Bio Reports Preclinical Data Validating a Conserved Mechanism of Inhibition of NAD Hydrolases Implicated in Neurodegeneration in Neuron

– Potent, uncompetitive inhibitors of the pro-degenerative NADase SARM1 reported

– Molecular basis of product-assisted inhibition of NAD hydrolases like SARM1 and CD38 that have been implicated in neurological diseases elucidated

– Research supports Nura Bio’s goal of entering First-in-Human trials with oral, brain-penetrant SARM1 inhibitors in early 2023

Excerpt from the Press Release:

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Nura Bio Inc., a biopharma company based in South San Francisco, focused on the discovery and development of disease-modifying neuroprotective drugs, today announced the publication of research elucidating the molecular details of a conserved, NAD-dependent inhibitory mechanism that results in highly potent small molecule inhibitors of NAD hydrolases like SARM1 and CD38. . The publication also discloses several highly potent small molecule inhibitors of SARM1.” The study, titled “Uncompetitive, adduct forming SARM1 inhibitors are neuroprotective in preclinical models of nerve injury and disease”, by Bratkowski et al., was published online in Neuron and will appear in the November issue of the journal.

“Deploying high-resolution structures and sophisticated mechanistic models, our scientific team at Nura Bio has validated a conserved, NAD-dependent mechanism of inhibition of NAD hydrolases like SARM1 and CD38 as a viable therapeutic strategy for neuroprotection,” said Shilpa Sambashivan, PhD, lead author and Chief Scientific Officer at Nura Bio. “ We show that these inhibitors achieve potent inhibition of hydrolase activity by forming a conjugate with a product of the hydrolysis reaction resulting in inhibitors that confer significant structural and functional protection in preclinical models of neurological injury and disease.”

Since its conception in 2018, Nura Bio has been steadily growing a differentiated, small molecule pipeline focused on targets implicated in driving axon degeneration and neuroinflammation in neurological diseases. Nura Bio’s lead program, the SARM1 inhibitor program is currently in IND-enabling studies with the goal of entering First-in-Human trials in early 2023.

Click the button below to read the entire Press Release:

Continue Reading The Press Release